AMA and EMA issue joint guidance on Ebola vaccine development

Synopsis

EMA’s Emergency Task Force (ETF) and the African Medicines Agency (AMA) have published a joint position paper to support the timely start of clinical trials for potential vaccines against Ebola disease caused by Bundibugyo virus (BDBV). The position paper outlines the minimum requirements to start clinical trials and provides advice on trial design.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.